What is REGN revenue?

Regeneron Pharmaceuticals Inc. (REGN) reported $16.90B of revenue for the twelve months ended Sep 30, 2026. That is up 18.6% from the year before. Revenue for fiscal 2025 was $14.34B.

Yes. Regeneron Pharmaceuticals Inc. earned $4.82B in net income for the twelve months ended Sep 30, 2026, a net margin of 28.5%.

How much cash and debt does REGN have?

Regeneron Pharmaceuticals Inc. reported $3.66B in cash and cash equivalents and $1.99B of debt on its most recent balance sheet in SEC filings.

How fast is REGN revenue growing?

Regeneron Pharmaceuticals Inc.'s revenue changed +1.0% in fiscal 2025, to $14.34B. Its compound annual growth rate was +11.0% over 5 years and +13.3% over 10 years.

What is REGN free cash flow?

Regeneron Pharmaceuticals Inc. generated $3.83B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $4.85B less capital expenditures.

What is REGN earnings per share?

Diluted earnings per share were $45.21 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did REGN last report financial results?

The latest statements here come from Regeneron Pharmaceuticals Inc.'s 10-Q filed on Oct 30, 2026, covering the period ended Sep 30, 2026.

Financials · REGN

Regeneron Pharmaceuticals Inc. (REGN) financials

For the twelve months ended Sep 30, 2026, Regeneron Pharmaceuticals Inc. reported $16.90B of revenue and $4.82B of net income.

Revenue, TTM: $16.90B
Revenue growth, YoY: +18.6%
Net income, TTM: $4.82B
Net income growth, YoY: +5.2%
Net margin: 28.5%
Free cash flow, TTM: $3.83B
EPS, diluted, TTM: $45.21
EPS growth, YoY: +8.1%
Cash: $3.66B
Total debt: $1.99B
P/E: 19.67
P/S: 5.61
Market cap: $94.76B

Annual revenue$14.34B

FY2016FY2025

Annual net income$4.50B

FY2016FY2025

Annual free cash flow$4.08B

FY2016FY2025

REGN revenue and earnings growth

REGN revenueQ3 2026$5.12B

Quarter YoY: +36.3%
QoQ: +19.2%
FY YoY: +1.0%
5Y CAGR: +11.0%
10Y CAGR: +13.3%

REGN revenue was $5.12B in fiscal Q3 2026 (ended Sep 30, 2026), up 36.3% from a year earlier and up 19.2% from the prior quarter. For the full fiscal 2025 it was $14.34B, up 1.0% from fiscal 2024. Compound annual growth was +11.0% over 5 years and +13.3% over 10 years. It rose in 8 of the last 10 fiscal years.

REGN net incomeQ3 2026$1.95B

Quarter YoY: +33.5%
QoQ: +50.3%
FY YoY: +2.1%
5Y CAGR: +5.1%
10Y CAGR: +21.6%

REGN net income was $1.95B in fiscal Q3 2026 (ended Sep 30, 2026), up 33.5% from a year earlier and up 50.3% from the prior quarter. For the full fiscal 2025 it was $4.50B, up 2.1% from fiscal 2024. Compound annual growth was +5.1% over 5 years and +21.6% over 10 years. It rose in 7 of the last 10 fiscal years.

REGN EPSQ3 2026$18.45

Quarter YoY: +35.5%
QoQ: +50.9%
FY YoY: +8.2%
5Y CAGR: +6.3%
10Y CAGR: +22.3%

REGN diluted EPS was $18.45 in fiscal Q3 2026 (ended Sep 30, 2026), up 35.5% from a year earlier and up 50.9% from the prior quarter. For the full fiscal 2025 it was $41.48, up 8.2% from fiscal 2024. Compound annual growth was +6.3% over 5 years and +22.3% over 10 years.

REGN free cash flowQ3 2026$1.48B

Quarter YoY: +4.6%
QoQ: +158.9%
FY YoY: +11.3%
5Y CAGR: +15.3%
10Y CAGR: +20.1%

REGN free cash flow was $1.48B in fiscal Q3 2026 (ended Sep 30, 2026), up 4.6% from a year earlier and up 158.9% from the prior quarter. For the full fiscal 2025 it was $4.08B, up 11.3% from fiscal 2024. Compound annual growth was +15.3% over 5 years and +20.1% over 10 years. It rose in 7 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$14.34B	$14.20B	$13.12B	$12.17B	$16.07B	$8.50B	$6.56B	$5.15B	$5.87B	$4.86B
Cost of revenue	-	-	-	-	-	-	$402.80M	$237.50M	$202.51M	$194.62M
Gross profit	-	-	-	-	-	-	$6.15B	$4.91B	$5.67B	$4.67B
Research and development	$5.85B	$5.13B	$4.44B	$3.59B	$2.86B	$2.65B	$2.45B	$1.47B	$2.08B	$2.05B
Selling, general and admin	$2.70B	$2.95B	$2.63B	$2.12B	$1.82B	$1.35B	$1.34B	$1.13B	$1.32B	$1.18B
Operating income	$3.58B	$3.99B	$4.05B	$4.74B	$8.95B	$3.58B	$2.21B	$2.53B	$2.08B	$1.33B
Interest expense	$43.80M	$55.20M	$73.00M	$59.40M	$57.30M	$56.90M	$30.20M	$28.20M	$25.10M	$7.20M
Pre-tax income	$5.23B	$4.78B	$4.20B	$4.86B	$9.33B	$3.81B	$2.43B	$2.55B	$2.08B	$1.33B
Income tax	$725.80M	$367.30M	$245.70M	$520.40M	$1.25B	$297.20M	$313.30M	$109.10M	$880.00M	$434.30M
Net income	$4.50B	$4.41B	$3.95B	$4.34B	$8.08B	$3.51B	$2.12B	$2.44B	$1.20B	$895.50M
EPS, basic	$43.07	$40.90	$37.05	$40.51	$76.40	$32.65	$19.38	$22.65	$11.27	$8.55
EPS, diluted	$41.48	$38.34	$34.77	$38.22	$71.97	$30.52	$18.46	$21.29	$10.34	$7.70
Diluted shares	108.6M	115.1M	113.7M	113.5M	112.2M	115.1M	114.6M	114.8M	115.9M	116.3M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$3.12B	$2.49B	$2.73B	$3.12B	$2.90B	$2.21B	$1.63B	$1.48B	$825.20M	$547.70M
Short-term investments	$5.49B	$6.52B	$8.11B	$4.64B	$2.81B	$1.39B	$1.60B	$1.34B	$596.80M	$503.48M
Receivables	$5.74B	$6.21B	$5.67B	$5.33B	$6.04B	$4.11B	$2.10B	$1.72B	$1.54B	$1.34B
Inventory	$3.20B	$3.09B	$2.58B	$2.40B	$1.95B	$1.92B	$1.42B	$1.15B	$726.10M	$399.36M
Current assets	$18.02B	$18.66B	$19.48B	$15.88B	$14.01B	$9.78B	$7.69B	$6.45B	$4.33B	$3.18B
Total assets	$40.56B	$37.76B	$33.08B	$29.21B	$25.43B	$17.16B	$14.81B	$11.73B	$8.76B	$6.97B
Current liabilities	$4.37B	$3.94B	$3.42B	$3.14B	$3.93B	$2.70B	$2.10B	$1.44B	$1.14B	$1.24B
Short-term debt	-	-	-	-	-	-	$0	-	-	-
Long-term debt	$1.99B	$1.98B	$1.98B	$1.98B	$1.98B	$1.98B	$0	-	-	-
Total debt	$1.99B	$1.98B	$1.98B	$1.98B	$1.98B	$1.98B	$0	-	-	-
Total liabilities	$9.30B	$8.41B	$7.11B	$6.55B	$6.67B	$6.14B	$3.72B	$2.98B	$2.62B	$2.52B
Shareholders' equity	$31.26B	$29.35B	$25.97B	$22.66B	$18.77B	$11.03B	$11.09B	$8.76B	$6.14B	$4.45B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$4.98B	$4.42B	$4.59B	$5.01B	$7.08B	$2.62B	$2.43B	$2.20B	$1.31B	$1.49B
Capital expenditures	$898.40M	$755.90M	$718.60M	$590.10M	$551.90M	$614.60M	$429.60M	$383.10M	$272.60M	$511.90M
Free cash flow	$4.08B	$3.66B	$3.88B	$4.42B	$6.53B	$2.00B	$2.00B	$1.81B	$1.03B	$974.00M
Investing cash flow	-$629.10M	-$2.47B	-$3.19B	-$3.78B	-$5.38B	-$70.60M	-$2.03B	-$1.46B	-$1.01B	-$1.05B
Financing cash flow	-$3.72B	-$2.20B	-$1.79B	-$1.01B	-$1.01B	-$1.97B	-$252.10M	-$77.10M	-$24.40M	-$700.50M
Dividends paid	$370.30M	$0	$0	-	-	-	-	-	-	-
Share repurchases	$3.44B	$2.60B	$2.23B	$2.08B	$1.65B	$5.85B	$275.90M	$4.40M	$0	$0
Stock-based compensation	$993.70M	$982.80M	$885.00M	$725.00M	$601.70M	$432.00M	$464.30M	$427.40M	$507.30M	$559.90M
Depreciation and amortization	$543.70M	$482.90M	$421.00M	$341.40M	$286.20M	$235.90M	$210.30M	$148.20M	$145.50M	$104.70M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	1.0%	8.3%	7.8%	-24.3%	89.1%	29.6%	27.4%	-12.4%	20.8%	18.4%
Net income growth, YoY	2.1%	11.6%	-8.9%	-46.3%	129.9%	66.0%	-13.4%	104.0%	33.8%	40.8%
EPS growth, YoY	8.2%	10.3%	-9.0%	-46.9%	135.8%	65.3%	-13.3%	105.9%	34.3%	39.5%
Gross margin	-	-	-	-	-	-	93.9%	95.4%	96.6%	96.0%
Operating margin	24.9%	28.1%	30.9%	38.9%	55.7%	42.1%	33.7%	49.3%	35.4%	27.4%
Net margin	31.4%	31.1%	30.1%	35.6%	50.2%	41.3%	32.3%	47.5%	20.4%	18.4%
Free cash flow margin	28.4%	25.8%	29.5%	36.3%	40.6%	23.6%	30.5%	35.2%	17.6%	20.0%
Return on equity	14.4%	15.0%	15.2%	19.1%	43.0%	31.9%	19.1%	27.9%	19.5%	20.1%
Return on assets	11.1%	11.7%	12.0%	14.9%	31.7%	20.5%	14.3%	20.8%	13.7%	12.8%
Current ratio	4.13	4.73	5.69	5.06	3.56	3.63	3.67	4.47	3.82	2.56
Debt to equity	0.06	0.07	0.08	0.09	0.11	0.18	0.00	-	-	-

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$5.12B	$4.29B	$3.61B	$3.88B	$3.75B	$3.68B	$3.03B	$3.79B	$3.72B	$3.55B	$3.15B	$3.43B
Research and development	$1.79B	$1.63B	$1.54B	$1.63B	$1.48B	$1.42B	$1.33B	$1.41B	$1.27B	$1.20B	$1.25B	$1.18B
Selling, general and admin	$677.80M	$662.10M	$647.70M	$775.00M	$657.80M	$634.20M	$633.00M	$792.20M	$714.40M	$758.80M	$689.00M	$737.70M
Operating income	$2.05B	$1.29B	$642.90M	$879.90M	$1.03B	$1.08B	$591.70M	$990.20M	$1.18B	$1.07B	$751.40M	$972.90M
Interest expense	$10.60M	$11.00M	$12.90M	$12.20M	$19.30M	$3.60M	$8.70M	$10.50M	$13.80M	$14.80M	$16.10M	$18.30M
Pre-tax income	$2.28B	$1.53B	$831.20M	$1.04B	$1.76B	$1.52B	$905.00M	$958.10M	$1.49B	$1.63B	$700.70M	$1.15B
Income tax	$335.40M	$230.90M	$104.00M	$199.10M	$303.30M	$127.10M	$96.30M	$40.40M	$152.40M	$195.80M	-$21.30M	-$12.00M
Net income	$1.95B	$1.30B	$727.20M	$844.60M	$1.46B	$1.39B	$808.70M	$917.70M	$1.34B	$1.43B	$722.00M	$1.16B
EPS, basic	$19.16	$12.62	$6.99	$8.16	$14.09	$13.24	$7.58	$8.55	$12.40	$13.25	$6.70	$10.88
EPS, diluted	$18.45	$12.23	$6.75	$7.78	$13.62	$12.81	$7.27	$8.12	$11.54	$12.41	$6.27	$10.21
Diluted shares	105.6M	106.0M	107.7M	-	107.2M	108.6M	111.2M	-	116.2M	115.4M	115.1M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$3.66B	$2.46B	$2.96B	$3.12B	$2.51B	$2.00B	$3.09B	$2.49B	$2.01B	$1.92B	$2.60B	$2.73B
Short-term investments	$5.64B	$5.54B	$5.79B	$5.49B	$5.94B	$5.47B	$5.26B	$6.52B	$7.78B	$7.89B	$7.92B	$8.11B
Receivables	$7.58B	$6.57B	$5.73B	$5.74B	$5.69B	$5.61B	$5.56B	$6.21B	$6.11B	$5.72B	$5.22B	$5.67B
Inventory	$2.89B	$3.08B	$3.10B	$3.20B	$3.25B	$3.21B	$3.19B	$3.09B	$3.02B	$2.87B	$2.71B	$2.58B
Current assets	$20.80B	$18.45B	$18.21B	$18.02B	$17.98B	$16.86B	$17.57B	$18.66B	$19.33B	$19.08B	$18.87B	$19.48B
Total assets	$44.41B	$41.73B	$40.87B	$40.56B	$40.17B	$38.22B	$37.55B	$37.76B	$37.44B	$36.09B	$34.37B	$33.08B
Current liabilities	$6.20B	$5.53B	$5.11B	$4.37B	$4.43B	$3.67B	$3.57B	$3.94B	$3.66B	$3.51B	$3.58B	$3.42B
Long-term debt	$1.99B	$1.99B	$1.99B	$1.99B	$1.99B	$1.99B	$1.98B	$1.98B	$1.98B	$1.98B	$1.98B	$1.98B
Total debt	$1.99B	$1.99B	$1.99B	$1.99B	$1.99B	$1.99B	$1.98B	$1.98B	$1.98B	$1.98B	$1.98B	$1.98B
Total liabilities	$10.91B	$10.02B	$9.45B	$9.30B	$9.21B	$8.28B	$8.16B	$8.41B	$8.12B	$7.88B	$7.38B	$7.11B
Shareholders' equity	$33.50B	$31.71B	$31.42B	$31.26B	$30.96B	$29.94B	$29.39B	$29.35B	$29.33B	$28.21B	$26.99B	$25.97B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$1.78B	$813.00M	$1.08B	$1.17B	$1.62B	$1.14B	$1.05B	$1.26B	$1.29B	$354.00M	$1.51B	$1.09B
Capital expenditures	$300.20M	$240.20M	$230.60M	$248.70M	$201.40M	$219.00M	$229.30M	$199.60M	$241.90M	$180.50M	$133.90M	$251.40M
Free cash flow	$1.48B	$572.80M	$848.30M	$922.00M	$1.42B	$925.40M	$815.80M	$1.06B	$1.05B	$173.50M	$1.38B	$838.30M
Investing cash flow	-$288.10M	-$92.70M	-$428.90M	$220.30M	-$402.90M	-$1.09B	$647.50M	$350.60M	-$574.40M	-$557.20M	-$1.69B	-$66.20M
Financing cash flow	-$290.20M	-$1.22B	-$802.20M	-$780.10M	-$717.90M	-$1.13B	-$1.09B	-$1.14B	-$634.00M	-$478.10M	$47.10M	-$446.10M
Dividends paid	$95.70M	$96.80M	$97.80M	$92.70M	$91.20M	$92.60M	$93.80M	$0	$0	$0	$0	-
Share repurchases	$399.70M	$1.17B	$794.30M	$671.70M	$664.00M	$1.06B	$1.04B	$973.00M	$735.10M	$603.90M	$291.30M	$289.00M
Stock-based compensation	$255.80M	$243.00M	$257.40M	$249.30M	$237.00M	$251.70M	$255.70M	$304.40M	$225.10M	$223.20M	$230.10M	$240.40M
Depreciation and amortization	$121.00M	$123.70M	$123.20M	$145.00M	$136.70M	$135.10M	$126.90M	$126.40M	$121.70M	$120.70M	$114.10M	$113.00M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	36.3%	16.7%	19.0%	2.5%	0.9%	3.6%	-3.7%	10.3%	10.6%	12.3%	-0.5%	0.6%
Net income growth, YoY	33.5%	-6.8%	-10.1%	-8.0%	8.9%	-2.8%	12.0%	-20.9%	33.0%	47.9%	-11.7%	-3.1%
EPS growth, YoY	35.5%	-4.5%	-7.2%	-4.2%	18.0%	3.2%	15.9%	-20.5%	29.8%	46.0%	-12.6%	-2.6%
Operating margin	40.0%	30.1%	17.8%	22.7%	27.3%	29.4%	19.5%	26.1%	31.7%	30.2%	23.9%	28.3%
Net margin	38.1%	30.2%	20.2%	21.7%	38.9%	37.9%	26.7%	24.2%	36.0%	40.4%	23.0%	33.8%
Free cash flow margin	29.0%	13.3%	23.5%	23.7%	37.8%	25.2%	26.9%	28.1%	28.2%	4.9%	43.8%	24.4%
Current ratio	3.35	3.34	3.57	4.13	4.06	4.60	4.93	4.73	5.28	5.44	5.27	5.69
Debt to equity	0.06	0.06	0.06	0.06	0.06	0.07	0.07	0.07	0.07	0.07	0.07	0.08

Source: XBRL data Regeneron Pharmaceuticals Inc. files with the SEC, latest filing dated Oct 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

REGN peers

Company	Revenue	Growth	Net income	Net margin	Market cap
REGN	$16.90B	+18.6%	$4.82B	28.5%	$94.76B
ABBVAbbVie Inc.	$66.01B	+10.7%	$10.34B	15.7%	$519.48B
MRKMerck & Company Inc.	$67.38B	+4.9%	$2.45B	3.6%	$364.98B
SNYSanofi	€43.63B	+6.2%	€7.81B	17.9%	$117.63B

REGN FAQ

8 questions

What is REGN revenue?
Regeneron Pharmaceuticals Inc. (REGN) reported $16.90B of revenue for the twelve months ended Sep 30, 2026. That is up 18.6% from the year before. Revenue for fiscal 2025 was $14.34B.
Is REGN profitable?
Yes. Regeneron Pharmaceuticals Inc. earned $4.82B in net income for the twelve months ended Sep 30, 2026, a net margin of 28.5%.
How much cash and debt does REGN have?
Regeneron Pharmaceuticals Inc. reported $3.66B in cash and cash equivalents and $1.99B of debt on its most recent balance sheet in SEC filings.
How fast is REGN revenue growing?
Regeneron Pharmaceuticals Inc.'s revenue changed +1.0% in fiscal 2025, to $14.34B. Its compound annual growth rate was +11.0% over 5 years and +13.3% over 10 years.
What is REGN free cash flow?
Regeneron Pharmaceuticals Inc. generated $3.83B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $4.85B less capital expenditures.
What is REGN earnings per share?
Diluted earnings per share were $45.21 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did REGN last report financial results?
The latest statements here come from Regeneron Pharmaceuticals Inc.'s 10-Q filed on Oct 30, 2026, covering the period ended Sep 30, 2026.
Where does this REGN financial data come from?
Quantisnow builds these statements from the structured XBRL data Regeneron Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.